Esocazol

Esocazol

esomeprazole

Manufacturer:

Caprifarmindo
Concise Prescribing Info
Contents
Esomeprazole
Indications/Uses
Gastric antisecretory when oral route is not possible eg, GERD in patients w/ esophagitis &/or severe reflux symptoms; healing of gastric ulcers associated w/ NSAID therapy. Short-term maintenance of haemostasis & prevention of rebleeding in patients following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Dosage/Direction for Use
IV inj or infusion Adult Gastric antisecretory 20-40 mg once daily. Reflux oesophagitis 40 mg once daily. Symptomatic treatment of reflux disease; healing of gastric ulcers associated w/ NSAID therapy 20 mg once daily. Maintenance of haemostasis & prevention of gastric & duodenal ulcer rebleeding Following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg as bolus infusion over 30 min, followed by continuous IV infusion of 8 mg/hr for 3 days (72 hr). The parenteral treatment period should be followed by acid-suppression therapy w/ esomeprazole 40 mg tab once daily for 4 wk. Severe hepatic impairment: GERD Max: 20 mg daily; bleeding ulcers Initially 80 mg as bolus infusion, followed by 4 mg/hr continuous IV infusion for 71.5 hr.
Contraindications
Hypersensitivity to esomeprazole, substituted benzimidazole. Concomitant administration w/ atazanavir & nelvinavir is not recommended.
Special Precautions
Exclude malignancy in the presence of significant unintentional wt loss, recurrent vomiting, dysphagia, haematemesis or melaena & when gastric ulcer is suspected or present. Avoid concomitant use w/ clopidogrel. Patients at risk for developing osteoporosis or osteoporotic fractures. Severe renal insufficiency. Pregnancy. Not to be used during lactation; & in childn & adolescents.
Adverse Reactions
Headache; abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting; administration site reactions.
Drug Interactions
Decreased absorption of ketoconazole, itraconazole & erlotinib. Increased absorption & bioavailability of digoxin. Increased trough plasma levels of phenytoin in epileptic patients. Decreased exposure to the active metabolite of clopidogrel & max inhibition of (ADP induced) platelet aggregation. Increased MTX levels. Decreased serum levels of atazanavir & nelfinavir. Increased serum levels of saquinavir. Doubling of exposure w/ clarithromycin (CYP3A4 inhibitor) & voriconazole (CYP2C19 & CYP3A4 inhibitor). Decreased serum levels w/ rifampicin & St. John's wort.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Presentation/Packing
Form
Esocazol powd for inj 40 mg
Packing/Price
1's (Rp126,100/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in